By Sneha S K and Sahil Pandey
Dec 31 (Reuters) - The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal disorder, the company said on Wednesday.
Shares of the drugmaker were down 48% at $36.41.
The company said the FDA could not arrive at a favorable benefit-risk assessment for the hormone-blocking oral treatment, known as relacorilant, without Corcept providing additional evidence of effectiveness.
The company was seeking approval for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
"FDA's request for additional data may require additional trials, significantly dimming Corcept's outlook in Cushings," said Truist analyst Joon Lee.
Hypercortisolism, also known as Cushing's syndrome, occurs when the body is exposed to high cortisol activity.
Corcept had submitted trial data that showed that relacorilant made improvements in a wide array of hypercortisolism's signs and symptoms.
"We will meet with the FDA as soon as possible to discuss the best path forward," said Joseph Belanoff, Corcept's CEO.
Main symptoms of hypercortisolism include a fatty hump between the shoulders, a rounded face, and pink or purple stretch marks on the skin. People with Cushing's also experience diabetes, high blood pressure, muscle weakness and immune suppression.
Relacorilant is a selective cortisol modulator designed to block the effects of cortisol, while avoiding certain off‑target hormonal effects.
"Given the company had opportunities to address FDA's concerns during mid and late-stage reviews, it's unclear if any further dialogue can resolve the review issues without additional trials," Lee added.
Corcept is also studying the drug in a variety of serious disorders including ovarian and prostate cancer. Its other drug known as Korlym is approved to treat high blood sugar caused by hypercortisolism in adults with endogenous Cushing's syndrome.
Other approved treatments for Cushing's syndrome include Isturisa by Recordati and Xeris Biopharma's Recorlev.
(Reporting by Sahil Pandey and Sneha S K in Bengaluru; Editing by Shailesh Kuber)
LATEST POSTS
- 1
The most effective method to Explore Moral Situations in Brain research with Your Certification - 2Robyn returns to music with 'Dopamine,' her 1st single in 7 years: 'Came to save music once again'
- 3The Best 15 Applications for Efficiency and Association
- 4Getting breast implants was a mistake I live with every day. Why I’m sharing my story now, at 70, in pain and afraid.
- 5FDA claims on COVID-19 vaccine safety are unsupported by reliable data – and could severely hinder vaccine access
- A trip to Colombia in my 20s turned into 8 years freelancing in South America. Here's what I'd do differently.
- Unsold Rams May Be Less expensive Than You Suspect
- BHP liable for 2015 Brazil mine disaster: UK court
- Figure out How to Forestall Tooth Staining
- These HGTV stars made a pledge to keep their kids off smartphones. Here's how it's going.
- OECD: Iran war dampening global growth
- Turkey's Erdogan denounces Israel-Greece-Cyprus trilateral summit, affirms support for Gaza
- What you need to know about Trump accounts as Michael and Susan Dell donate $6 billion to the new early childhood investment program
- These 2 moon rovers used cameras and lasers to hunt for simulated water ice — and one looks like WALL-E
